Alnylam Pharmaceuticals INC (ALNY) Shareholder Gilder Gagnon Howe & Co LLC Increased Stake

April 16, 2018 - By Damon Whitfield

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Corporate LogoBig Money Sentiment increased to 2.03 in 2017 Q4. It has change of 1.11, from 2017Q3’s 0.92. The ratio increased due to ALNY positioning: 27 sold and 47 reduced. 67 funds amassed stakes and 83 increased stakes. Investors holded 86.02 million in 2017Q3 but now own 90.18 million shares or 4.83% more. Strs Ohio reported 0% of its capital in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Nomura Holding reported 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Comml Bank Of America De holds 0% of its capital in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 123,352 shs. Segall Bryant & Hamill Ltd Co has 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 2,000 shs. Tobam holds 111,554 shs. Moreover, Suntrust Banks has 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Vantage Inv Advsr Limited Liability Company invested in 0.01% or 255 shs. Point72 Asset Mgmt LP reported 88,886 shs. Royal National Bank Of Canada holds 0% or 2,687 shs. Morgan Stanley has invested 0.04% of its capital in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Glenmede Na owns 175 shs. Emory University holds 14,344 shs. Rhenman & Ptnrs Asset Mgmt Ab has 1.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). First Trust Advsrs Lp holds 0.17% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 571,398 shs. Kornitzer Cap Mngmt Ks stated it has 211,455 shs or 0.46% of all its holdings.

ALNY had 10 insider sales and 0 insider purchases since January 4, 2018. This’s net activity of $38.04 million. Another trade for 17,117 shs valued at $2.57 million was made by Ausiello Dennis A on Tuesday, March 13. Another trade for 15,000 shs valued at $2.24 million was made by SHARP PHILIP A on Tuesday, March 13. Shares for $234,033 were sold by KEATING LAURIE. 27,823 shs valued at $4.17M were sold by SCHIMMEL PAUL on Tuesday, March 13. The insider Greene Barry E sold $5.50M. The insider Vaishnaw Akshay sold 88,554 shs worth $12.67 million.

In 2017Q4 Securities and Exchange filling is reported Gilder Gagnon Howe & Co Llc’s stake in Alnylam Pharmaceuticals Inc (ALNY) which was increased by 8.64%. 96,812 shares were bought by Gilder Gagnon Howe & Co Llc as the company’s stock rose 5.82% while stock markets declined. The health care company at the end of 2017Q4 was priced at $154.67 million. It’s up from 1.12 million at the end of the previous reported quarter. Now it had 1.22 million shares held by the institutional investor . $9.78B is the market cap of Alnylam Pharmaceuticals Inc. The stock decreased 3.09% or $3.11 during the last trading session, reaching $97.65.Alnylam Pharmaceuticals, Inc. has volume of 346,753 shares. Since April 16, 2017 ALNY has risen 150.73% and is uptrending. The stock outperformed the S&P 500 by 139.18%.

Gilder Gagnon Howe & Co Llc operates about $6.26B and $7.44B US Long portfolio. It decreased its stake in Mimecast Limited Com Usd0.012 by 141,972 shares to 33,650 shares, valued at $965,000 in 2017Q4, according to the filing. For a total of 1.56 million shares it reduced its holding in Shake Shack Inc Cl A by 71,834 shares in the quarter, and has cut its stake in First Rep Bk San Francisco Cal Com (NYSE:FRC).

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Total analysts of 15 have positions in Alnylam Pharmaceuticals (NASDAQ:ALNY) as follows: 11 rated it a “Buy”, 1 with “Sell” and 3 with “Hold”. The positive are 73%. Since October 30, 2017 according to StockzIntelligence Inc Alnylam Pharmaceuticals has 30 analyst reports. On Friday, December 15 the rating was maintained by Piper Jaffray with “Buy”. On Friday, November 3 the stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Outperform” rating given by Credit Suisse. On Thursday, January 25 the firm has “Market Perform” rating by Leerink Swann given. On Thursday, March 22 Piper Jaffray maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating. Piper Jaffray has “Buy” rating and $182.0 target. In Wednesday, November 8 report BMO Capital Markets maintained it with “Buy” rating and $168.0 target. On Wednesday, March 28 the stock has “Buy” rating by FBR Capital. On Monday, January 8 the firm has “Buy” rating by Jefferies given. On Friday, February 9 Nomura maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with “Sell” rating. On Wednesday, November 8 the firm has “Overweight” rating by Barclays Capital given. On Friday, February 2 the stock has “Buy” rating by FBR Capital.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.